![Christy Oliger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 96 450 $ in data 30/09/2026
Ms. Christy J.
Oliger is an Independent Director at Zenas BioPharma, Inc., an Independent Director at Bicara Therapeutics, Inc., an Independent Director at Vera Therapeutics, Inc., an Independent Director at Replimune Group, Inc. and an Independent Director at Karyopharm Therapeutics, Inc. She is on the Board of Directors at Zenas BioPharma, Inc., Bicara Therapeutics, Inc., Vera Therapeutics, Inc., Replimune Group, Inc., Karyopharm Therapeutics, Inc. and Replimune, Inc. Ms. Oliger was previously employed as an Independent Director by Nuvalent, Inc., an Independent Non-Executive Director by LAVA Therapeutics NV, an Independent Director by Sierra Oncology, Inc., an Independent Director by Reata Pharmaceuticals, Inc., and a Senior Vice President-Oncology Business Unit by Genentech, Inc. She also served on the board at Rayzebio, Inc. She received her undergraduate degree from the University of California, Santa Barbara.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 21/05/2026 | 2.987 ( 0% ) | 96 450 $ | 30/09/2026 | |
| 30/06/2026 | 0 ( -.--% ) | - $ | 30/09/2026 | |
| 21/05/2026 | 0 ( -.--% ) | - $ | 30/09/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Direttore/Membro del Consiglio | 28/08/2020 |
| REPLIMUNE GROUP, INC. | Direttore/Membro del Consiglio | 01/12/2021 |
| VERA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 07/06/2024 |
| BICARA THERAPEUTICS INC. | Direttore/Membro del Consiglio | 28/07/2026 |
Replimune, Inc.
 Replimune, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune, Inc. is an American clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies using its proprietary RPx platform, which is based on a herpes simplex virus type 1 backbone engineered to selectively destroy tumor cells, modify the tumor microenvironment, and induce a systemic anti-tumor immune response with enhanced T-cell activation. The company is located in the US. The company’s therapies are designed for direct injection into tumors to trigger local destruction and systemic immune activation, potentially overcoming resistance to existing immunotherapies. Its clinical pipeline includes candidates such as RP1 and RP2, being evaluated in advanced melanoma, non-melanoma skin cancers, metastatic uveal melanoma, and hepatocellular carcinoma. Key clinical trials include the phase 3 IGNYTE-3 trial of RP1 with nivolumab in advanced melanoma, the ARTACUS trial for transplant patients with skin cancers, the REVEAL study in uveal melanoma, and the RP2-003 trial in liver cancer. Replimune retains commercial rights to its therapies and collaborates with partners for supply of checkpoint inhibitors used in combination regimens. The company also supports independent clinical investigations and funds medical education initiatives in oncology. | Direttore/Membro del Consiglio | - |
| Società | Posizione | Fine |
|---|---|---|
| NUVALENT, INC. | Direttore/Membro del Consiglio | 15/07/2026 |
| LAVA THERAPEUTICS | Direttore/Membro del Consiglio | 07/11/2025 |
| RAYZEBIO, INC. | Direttore/Membro del Consiglio | 26/02/2024 |
| REATA PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 01/06/2023 |
| ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 12 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Develops novel therapeutic approaches for cancer and other diseases | Health Technology |
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics which regulates cellular metabolism and inflammation in serious neurologic diseases | Health Technology |
University of California, Santa Barbara
 University of California, Santa Barbara Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Karyopharm Therapeutics, Inc.
 Karyopharm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation | Health Technology |
Replimune Group, Inc.
 Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
LAVA Therapeutics NV
 LAVA Therapeutics NV Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops antibodies for the treatment of cancer | Health Technology |
Replimune, Inc.
Replimune, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune, Inc. is an American clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies using its proprietary RPx platform, which is based on a herpes simplex virus type 1 backbone engineered to selectively destroy tumor cells, modify the tumor microenvironment, and induce a systemic anti-tumor immune response with enhanced T-cell activation. The company is located in the US. The company’s therapies are designed for direct injection into tumors to trigger local destruction and systemic immune activation, potentially overcoming resistance to existing immunotherapies. Its clinical pipeline includes candidates such as RP1 and RP2, being evaluated in advanced melanoma, non-melanoma skin cancers, metastatic uveal melanoma, and hepatocellular carcinoma. Key clinical trials include the phase 3 IGNYTE-3 trial of RP1 with nivolumab in advanced melanoma, the ARTACUS trial for transplant patients with skin cancers, the REVEAL study in uveal melanoma, and the RP2-003 trial in liver cancer. Replimune retains commercial rights to its therapies and collaborates with partners for supply of checkpoint inhibitors used in combination regimens. The company also supports independent clinical investigations and funds medical education initiatives in oncology. | Commercial Services |
Vera Therapeutics, Inc.
 Vera Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company, which focuses on development and treatments for immunological & inflammatory diseases | Health Technology |
Bicara Therapeutics, Inc.
 Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and sells therapeutics for tumors | Health Technology |
Nuvalent, Inc.
 Nuvalent, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of targeted therapies for patients with cancer | Health Technology |
Rayzebio, Inc.
 Rayzebio, Inc. Pharmaceuticals: MajorHealth Technology Develops radiopharmaceutical therapeutics for cancer treatment | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
